CD274 and non-small cell lung carcinoma: Exceptions include the use of pembrolizumab at the first and second line of NSCLC, which requires PD-L1 expression levels of ≥50% and ≥1% respectively, as well as the site agnostic indication for mismatch repair deficient tumors.